PST
PST Inc. is a Yokohama-based biotechnology company that develops vocal biomarker technology analyzing voice source features to detect mental, neurological, cardiovascular, and cognitive health conditions, serving enterprise employers, transportation operators, medical institutions, and municipalities via its VOISLOG cloud platform and regulated SaMD programs.
- Company typePrivate
- Founded2012
- HeadquartersYokohama, Japan
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What PST does
PST Inc. is a Yokohama-based biotechnology company founded in 2012 that develops and commercializes vocal biomarker (音声バイオマーカー) technology for medical and healthcare applications. Its core technology analyzes raw voice source signals — specifically involuntary vocal cord tension changes controlled by the vagus nerve, combined with expiratory pressure and vocal tract modulation — to detect mental, neurological, cardiovascular, and systemic health conditions. This analysis is language-agnostic and unaffected by a speaker's intentional voice modulation because it operates on the acoustic source rather than linguistic content. The proprietary Mi-1 AI model and feature extraction algorithms (ALVI, MDVI) are backed by 10+ years of R&D originating from the University of Tokyo voice pathophysiology laboratory, with multiple peer-reviewed publications across depression, heart failure, cognitive impairment, and COVID-19 severity domains.
PST operates two product lines. The first is VOISLOG, a cloud-based healthcare platform launched in July 2024 that includes smartphone voice analysis apps (vAnalysis individual and shared), a remote-meeting voice analysis tool (vBG App integrating Zoom/Teams/Slack/Google Meet/LINE/Webex), an administrative dashboard (vManagement) with monthly Personal Reports, and an EQ quantification module (vEQ). Disease-specific biomarkers (VOISFIA) and legacy MIMOSYS technology serve the medical domain. The second is regulated medical device development via wholly-owned subsidiary PST Medical Inc., established January 2024, which holds a Class II Medical Device Manufacturing and Sales License (obtained June 2024) and is pursuing SaMD approval for depression severity assessment under Tokyo's AMDAP program.
PST generates revenue through VOISLOG cloud subscriptions (enterprise and SMB tiers), OEM/cloud licensing to platform partners (NTT Data BXO, Kort Valuta TwooCa, Wellville LIFE TALK ENGINE), WebAPI licensing, and future regulated SaMD sales via PST Medical. Go-to-market combines enterprise direct sales, channel partners (Hino Computer Systems for transportation), co-development partnerships with strategic players (Rohto Pharmaceutical, WISDOM, Sekisui Chemical, SOMPO), and government/municipal collaborations (Kanagawa Prefecture, Tokyo AMDAP). Customer segments span enterprise employers, transportation/logistics operators, nursing care facilities, SMBs (via government subsidy program), medical institutions, and local governments. The company received the EY Innovative Startup 2026 award and ASCO Breakthrough 2024 Abstract Award, among other recognitions.
PST firmographics
Firmographics- Name
- PST
- Legal name
- PST株式会社
- Website
- https://medical-pst.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PST Inc. is a Yokohama-based biotechnology company that develops vocal biomarker technology analyzing voice source features to detect mental, neurological, cardiovascular, and cognitive health conditions, serving enterprise employers, transportation operators, medical institutions, and municipalities via its VOISLOG cloud platform and regulated SaMD programs.
- Ownership category
- akta.pro rank
PST industry classification
Industry- Product category
- Voice-Based Health Diagnostics and Wellness Software
- NAICS
- Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
- akta.pro secondary industries
- Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD), SaMD – Monitoring, Triage & Risk Stratification Software (HLACANAE), Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN) (HLALADAD)
Keywords
Where PST is headquartered
LocationHeadquarters
- HQ city
- Yokohama
- HQ country
- Japan
- HQ region
- Asia
Offices2 records
Markets served
PST business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D
Revenue model
- VOISLOG cloud platform subscription: VOISLOG is offered as a cloud-based SaaS platform with multiple apps (vAnalysis shared, vBG App) and management console (vManagement). Customers subscribe to access voice AI analysis and reporting. Revenue is primarily subscription-based with per-seat or organization-level pricing.
- IT導入支援事業者 subsidy (VOISLOG Standard Pack): VOISLOG標準パック[vAs+vM] is registered as an IT tool under the 中小企业デジタル化・AI導入支援事業費補助金, enabling SME customers to receive up to ¥1.5M in government subsidies toward subscription costs.
- OEM/cloud system licensing: PST provides cloud systems and WebAPI to OEM partners (enterprises, platforms) who embed voice biomarker technology into their own products and services. Partners integrate via API and pay licensing fees.
- Medical device software (SaMD) development and sales (PST Medical): PST Medical (subsidiary) is developing regulated medical device programs (Software as a Medical Device) for depression severity assessment and other clinical applications. Business model targets medical institutions and healthcare providers upon regulatory approval.
- Platform integration services (TwooCa, BXO): PST technology embedded in partner platforms (Kort Valuta TwooCa, NTT Data BXO) as licensed voice analysis engine, generating recurring licensing revenue from platform operators.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | VOISLOG標準パック [vAs+vM] — voice analysis app (vAnalysis shared) + management console (vManagement) |
Go-to-market motion4 records
Distribution channels6 records
Marketing channels8 records
PST product offering
Product offeringCore offering
PST develops and sells a cloud-based vocal biomarker platform called VOISLOG that analyzes voice source features (not linguistic content) to detect mental, cognitive, cardiovascular, and physiological health conditions for enterprise wellness, transportation safety, elderly care, and clinical psychiatry applications. Through its subsidiary PST Medical, the company develops regulated Software as a Medical Device (SaMD) programs for depression severity assessment and cognitive screening, and operates the MIMOSYS legacy voice-based mental health monitoring system. Revenue is generated via SaaS subscriptions, OEM/API licensing, and government-subsidized SME deployments in Japan.
Product overview
PST Inc. operates as a vocal biomarker technology company offering two distinct product lines: (1) VOISLOG, a cloud-based healthcare voice analysis platform for corporate health management and wellness, and (2) disease-specific vocal biomarker technologies (VOISFIA) and medical device programs (SaMD) for the medical domain via its subsidiary PST Medical Inc. VOISLOG comprises multiple modules — voice analysis apps (vAnalysis individual and shared for shared devices), meeting-based analysis app (vBG App), administrative dashboards (vManagement), monthly Personal Report, and the vEQ emotional intelligence module — unified by the Mi-1 voice AI model. MIMOSYS is the legacy healthcare product. PST Medical focuses on clinical-grade depression severity assessment and cognitive screening as regulated medical devices. All technologies analyze raw voice source signals (not text) to detect involuntary physiological changes indicative of mental and physical health conditions.
Differentiator
Problem solved
Functional benefit
Brands
- VOISLOG®: 日常会話などの音声を解析しストレス、睡眠、認知機能などの健康指標を推定するクラウドベースの音声解析プラットフォーム。スマートフォンアプリ（vAnalysis、vAnalysis shared）、リモート会議ツール（vBG App）、WebAPI管理システム（vManagement）を含む。
- MIMOSYS®
- VOISFIA®
- PST Medical Inc. (PST MEDITCAL株式会社)
- vEQ（Vocal Emotional Intelligence Quotient）
Products and services
- VOISLOG Healthcare Platform Cloud-based voice analysis platform that visualizes mental and physical health conditions (stress, cognitive function, sleep, swallowing) from voice for corporate health management and wellness. Provides voice biomarker analysis via smartphone apps, remote meeting tools, WebAPI, and management dashboards for enterprise customers.
- Depression Severity Assessment Tool (PST Medical SaMD) Medical device program under development by PST Medical Inc. for depression severity assessment using voice biomarkers. Estimates HAM-D scores with r=0.579 Pearson correlation and ROC-AUC 0.78-0.80 for HAM-D thresholds. Targeting SaMD approval for use by psychiatric hospitals and clinics.
- Heart Failure Vocal Biomarker (VOISFIA) Disease-specific vocal biomarker for heart failure developed with Yokohama City University. Uses machine learning models with voice acoustic features to predict BNP levels (r=0.49) and NYHA class, achieving up to 80.4% accuracy in predicting cardiac test results for clinical use.
- vAnalysis shared (Shared-Device Voice Analysis App) Voice analysis app optimized for shared device use in workplace settings (transportation, call centers, enterprises). Allows approximately 50 users per shared tablet/phone with guided reading or free speech measurement, auto-login, brief result display, and automatic logout for secure multi-user operation.
- vBG App (Meeting Voice Analysis App) Desktop voice analysis app that runs in the background during remote or in-person meetings on Zoom, Microsoft Teams, Slack, Google Meet, LINE, and Webex. Automatically captures the registered user's voice only and analyzes stress and mental/physical condition changes without user intervention.
- vManagement Personal Report Monthly structured personal health report feature within vManagement. Consolidates 1 month of voice analysis results, providing numerical/graphical trends plus natural language commentary authored with occupational health expert input, including self-care action recommendations.
- vEQ (Vocal Emotional Intelligence Quotient Service) Voice-based Emotional Intelligence Quotient quantification service co-developed with WISDOM. Quantifies empathy from voice using the 'vEQ' empathy analysis algorithm (patent pending). Targets HR, talent development, and organizational EQ building for enterprise customers.
- MIMOSYS (Mind Monitoring System) PST's foundational voice-based mental health assessment technology that visualizes mental states by analyzing voice changes including involuntary vocal cord tension. Exports Vitality, Mental Activity, and Mind Index scores. Available via SDK, WebAPI, and applications for healthcare and enterprise customers.
- VOISLOG × TwooCa Ring Integration Integrated product combining VOISLOG voice biomarker analysis with the TwooCa Ring wearable device (Kort Valuta), merging voice analysis data with vital signs to generate composite health scores spanning physical, mental, and financial wellness for enterprise employees.
- VOISLOG Standard Pack [vAs+vM] Standardized IT tool package combining vAnalysis shared (vAs) and vManagement (vM) cloud services for SMEs. Registered as an approved IT tool under Japan's SMB Digitalization/AI Adoption Subsidy program, enabling eligible businesses to receive up to 1.5 million yen in government subsidies.
- Cognitive Impairment Screening Vocal Biomarker (VOISFIA) Disease-specific vocal biomarker for mild cognitive impairment (MCI) and dementia (Alzheimer's, DLB) developed with academic partners. Uses non-verbal acoustic features from simple speech tasks in machine learning models. Achieved mean AUC of 0.81 and 66.7% three-group correct classification (healthy/MCI/dementia) in validation.
Quantifiable outcome
- Depression estimation: Pearson r=0.579; ROC-AUC 0.793 (HAM-D≥8), 0.780 (HAM-D≥14). Inter-visit monitoring: correlation 0.62, AUC=0.82, 77% accuracy, marginal R²=0.37 for symptom change prediction.
- +4 more outcomes
Companies that use PST
Customer profileNamed customers6 records
Segments6 records
Ideal customer profiles5 records
PST technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration10 records
AI capability7 records
Feature13 records
PST partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered minor and core.
- E-Gaia Progress (株式会社イーガイアプログレス)minorJoint development of municipality/community mental health and well-being support services. Combine PST's VOISLOG platform with E-Gaia Progress's auto-call and WELLXiL mental health services. Target: elderly monitoring, community care, ME-BYO improvement. Extension of existing enterprise mental health partnership.
- WISDOM合同会社 (合同会社WISDOM)coreJoint development of vEQ (Vocal Emotional Intelligence Quotient) algorithm for quantifying empathy and EQ from voice. Patent filed jointly (特願2025-191230). WISDOM provides EQ training expertise; PST provides voice analysis technology. Target: enterprise EQ training (2026) and HR tech (2027+).
- Hino Computer Systems (日野コンピューターシステム)coreSales agent agreement for VOISLOG platform. Hino CS — IT provider within Hino Motor Group — distributes VOISLOG to transportation companies and other industries for driver condition monitoring at shift check-in and accident prevention.
- Tokyo Marine DR (東京海上ディーアール)minorCollaboration on enterprise health management consulting. Combines Tokyo Marine DR's risk consulting expertise with PST's voice biomarker technology for corporate wellness programs targeting mental health, turnover reduction, and accident prevention in call centers and logistics.
- Kanagawa Prefecture (神奈川県)coreFormal partnership agreement for voice-based ME-BYO indicator regional deployment. Upgrade of MIMOSYS to VOISLOG Mi-1. Collaboration on ME-BYO brand expansion, stress/cognitive/sleep/oral health service rollout, and community health improvement across Kanagawa Prefecture.
- Rohto Pharmaceutical Co., Ltd. (ロート製薬)coreStrategic alliance to integrate vocal biomarker technology into Rohto's health and wellness ecosystem. Combined expertise aimed at developing products and services for mental health and preventive care, leveraging Rohto's pharmaceutical and consumer health platform.
- Tokyo Metropolitan Government (AMDAP program)corePST Medical selected for Tokyo's Advanced Medical Device Acceleration Project (AMDAP). Receives 3-year intensive support including dedicated catalyst (regulatory expert) mentoring, clinical/regulatory/IP/business guidance for developing depression severity SaMD.
- Total Future Healthcare (トータルフューチャーヘルスケア)minorPST participates in Total Future Healthcare's cross-industry platform for early detection of falls and disease risk in living spaces. PST contributes voice biomarker data for health monitoring within the platform ecosystem.
- Kort Valuta (株式会社Kort Valuta)coreCapital and business alliance. PST technology integrated into Kort Valuta's TwooCa digital employee badge (Visa payment + attendance + mental health check). Also Kort Valuta ring vital data + VOISLOG integration planned. FinTech × HealthTech partnership for 'money, body, mind' health.
- Sekisui Chemical (積水化学工業)minorJoint development of cognitive function screening voice analysis algorithm. Clinical trial for cognitive function testing medical device initiated. Sekisui Chemical and PST co-developing the algorithm for commercialization.
- UIX Corporation (UIX株式会社)minorJoint venture (PST + FlexibleCreation) operating 'Sofuto Visiting Nursing Station' in Yokohama Isogo-ku. Next-generation visiting nursing service combining PST voice analysis, AI/IT technology, and cloud PBX with electric kickboard mobility.
- NTT Data Japan (株式会社NTTデータ)coreMIMOSYS voice biomarker technology OEM-integrated into NTT Data's BXO Hybrid Workspace for Employee Experience (BXO Well-being module). Enables NTT Data to offer voice-based mental health monitoring to enterprise clients in hybrid work environments.
- JST COI-NEXT Metaverse Platform (JST共創の場形成支援プログラム)minorPST participates in Yokohama City University-led 'Meta Care City' project (JST COI-NEXT 共創分野本格型). Contributes voice pathophysiology analysis as health quantification tool in virtual care environments targeting youth psychological resilience.
- SOMPO Holdings / SOMPO Care (積水化学工業+SOMPOケア)minorJoint R&D on swallowing function evaluation technology using voice analysis via smartphone/tablet. Aimed at visualizing aspiration risk in elderly populations. Planned 2022 commercialization.
- Kyoto University Hospital / Kyoto University Graduate School of Medicine (京都大学医学部附属病院・京都大学大学院医学研究科)coreJoint research on voice-based QOL management for gynecological cancer patients and depression assessment. Multiple papers published, ASCO Breakthrough Abstract Award received. Co-development of depression severity estimation model with 2026 clinical results published.
- Yokohama City University / Yokohama City University Medical Center (横浜市立大学・附属総合医療センター)coreLong-standing joint research on heart failure vocal biomarkers with Dr. Kozo Okada. Multiple publications including AHA Scientific Session, Japan Circulation Society, and Circulation Reports. Also collaborated on congenital heart disease seminar (2024).
- Welby (不是我认识的合作伙伴 - listed in joint users)minorListed in PST privacy policy joint user list.
- Kanagawa University of Human Services (神奈川県立保健福祉大学)minorJoint research with Prof. Shinichi Tokuno on COVID-19 severity discrimination from voice, published 2023 in Int J Env Res Public Health.
Scale indicators7 records
Recent moves7 records
Expansion highlights7 records
PST competitors and assessment
Company assessmentDirect peers
- Kintsugi: US-based voice biomarker startup quantifying depression/anxiety from short voice samples for payers and digital health platforms. Closely parallels PST's depression model, enterprise wellness integration and SDK/API distribution.
- Winterlight Labs: Canada-based voice biomarker company focused on cognitive and CNS endpoints for clinical trials (Alzheimer's, MCI, schizophrenia). Comparable to PST's cognitive impairment/dementia vocal biomarker module and clinical-research focus.
- Ellipsis Health: US-based vocal biomarker startup that analyzes voice to detect depression and anxiety symptoms for health systems and payers. Closely mirrors PST's depression/severe-mental-health scoring use case and clinical validation strategy.
- CureApp: Japanese digital therapeutics (DTx/SaMD) company with PMDA-approved nicotine-dependence and hypertension apps. Highly comparable to PST Medical on Japanese SaMD regulatory pathway, reimbursement and clinical-deployer GTM.
- Sonde Health: US-based vocal biomarker company offering voice-based mental and physical health monitoring (depression, stress, cognitive decline, respiratory conditions). Directly comparable to PST on technology approach, biomarker focus areas and SaaS/API delivery model.
Broad incumbents
- Omada Health: US-based broader digital health platform offering chronic condition prevention and management (diabetes, hypertension, mental health) to employers and payers. Comparable in B2B2C employer-wellness GTM and condition-specific digital interventions, though vaster scale and broader scope.
Regional players
- MICIN: Japanese digital health company offering online medical consultations, remote patient monitoring and AI-assisted triage to hospitals, pharmacies and insurers. Comparable regional peer serving overlapping Japanese enterprise/healthcare buyers with adjacent digital health services.
Emerging players
- Canary Speech: US-based vocal biomarker startup applying voice analysis to early detection of cognitive decline, mental health and neurodegenerative conditions. Overlaps with PST on vocal biomarker R&D focus, though still pre-commercial compared to PST's Japanese deployments.
- Beyond Verbal: Israel-based voice analysis company that decodes health and emotional biomarkers from vocal acoustics. Earlier-stage peer in the same vocal biomarker category as PST, with overlapping emotion/mood-disorder detection product thinking.
Others
- Modulate (Modulate AI): US-based voice analytics company that detects emotion, toxicity and engagement from speech on platforms like Discord and games. Adjacent rather than directly competitive, but comparable as a voice-as-signal AI infrastructure provider powering third-party platforms.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
PST social profiles
Digital presencePST compliance and trust
Trust signalCompliance2 records
PST financial estimates
Financial estimateRevenue estimate
Valuation estimate
PST leadership team
Management profileNumber of profiles
Profiles2 records
PST subsidiaries and ownership
Company hierarchySubsidiaries2 records
PST funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PST M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PST
What does PST do?
PST develops and sells a cloud-based vocal biomarker platform called VOISLOG that analyzes voice source features (not linguistic content) to detect mental, cognitive, cardiovascular, and physiological health conditions for enterprise wellness, transportation safety, elderly care, and clinical psychiatry applications. Through its subsidiary PST Medical, the company develops regulated Software as a Medical Device (SaMD) programs for depression severity assessment and cognitive screening, and operates the MIMOSYS legacy voice-based mental health monitoring system. Revenue is generated via SaaS subscriptions, OEM/API licensing, and government-subsidized SME deployments in Japan.
Is PST a public or private company?
PST is a private company. It is classified as venture growth investor backed and is currently operating.
When was PST founded?
PST was founded in 2012. It employs 11 to 50 people.
Where is PST based?
PST is headquartered in Yokohama, Japan, in the Asia region.
How does PST make money?
Five revenue lines are on record. VOISLOG cloud platform subscription is the primary driver. The others are IT導入支援事業者 subsidy (VOISLOG Standard Pack), OEM/cloud system licensing, medical device software (SaMD) development and sales (PST Medical) and platform integration services (TwooCa, BXO).
Who are PST's main competitors?
Direct peers on record are Kintsugi, Winterlight Labs, Ellipsis Health, CureApp and Sonde Health. Omada Health is listed as a broad incumbent. MICIN is listed as a regional player. Emerging players are Canary Speech and Beyond Verbal. Modulate (Modulate AI) is listed as an others.
Does PST have an API?
Yes. PST provides a WebAPI that customers can use online to implement various vocal biomarker technologies in their own applications. By posting acquired voice data to the WebAPI, customers can retrieve vocal biomarker data. Customers are responsible for implementing functions for voice data acquisition and building their own database for storing the retrieved vocal biomarker data. The WebAPI is offered as part of the VOISLOG platform's technology offerings for healthcare. The company also offers an SDK (Software Development Kit) as part of its historical MIMOSYS product line.
What industry is PST in?
PST's product category is Voice-Based Health Diagnostics and Wellness Software. Its primary akta.pro industry code is HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints, with a secondary code of HLACANAD, Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software. Its NAICS code is 5132 and its SIC code is 7372.